Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bicycle Therapeutics (BCYC – Research Report), Abbott Labs (ABT – Research Report) and VolitionRX (VNRX – Research Report).
Bicycle Therapeutics (BCYC)
Canaccord Genuity analyst William Maughan maintained a Buy rating on Bicycle Therapeutics yesterday and set a price target of $60.00. The company’s shares closed last Thursday at $15.25, close to its 52-week low of $14.80.
According to TipRanks.com, Maughan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.50.
See the top stocks recommended by analysts >>
Abbott Labs (ABT)
Bank of America Securities analyst Travis Steed maintained a Buy rating on Abbott Labs yesterday and set a price target of $115.00. The company’s shares closed last Thursday at $93.98, close to its 52-week low of $89.67.
According to TipRanks.com, Steed is a 3-star analyst with an average return of
Currently, the analyst consensus on Abbott Labs is a Strong Buy with an average price target of $118.00, implying a 26.8% upside from current levels. In a report issued on October 16, UBS also maintained a Buy rating on the stock with a $118.00 price target.
VolitionRX (VNRX)
In a report released today, Bruce Jackson from Benchmark Co. maintained a Hold rating on VolitionRX. The company’s shares closed last Thursday at $0.74, close to its 52-week low of $0.58.
According to TipRanks.com, Jackson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
VolitionRX has an analyst consensus of Moderate Buy, with a price target consensus of $2.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BCYC:
